Funding for this research was provided by:
Merck Sharp & Dohme Corp.
Received: 24 April 2020
Accepted: 5 October 2020
First Online: 27 October 2020
Ethics approval and consent to participate
: An independent ethics committee or institutional review board approved the final protocol at each study site. All patients provided written informed consent.
: Not applicable.
: Dr. Joyce O’Shaughnessy has received honoraria for consulting and advisory boards from AbbVie, Agendia, Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene Corporation, Eisai, Eli Lilly, Genentech, Genomic Health, GRAIL, Heron Therapeutics, Immunomedics, Ipsen Biopharmaceuticals, Jounce Therapeutics, Merck, Myriad, Novartis, Odonate Therapeutics, Pfizer, Puma Biotechnology, Roche, Seattle Genetics, and Syndax Pharmaceuticals.Dr. Christine Brezden-Masley has received honoraria for consulting and advisory boards from Amgen, AstraZeneca, Eli Lilly, Genomic Health, Merck, Myriad, Novartis, Pfizer, Roche, and Taiho. She has received travel grants from Amgen, AstraZeneca, and Roche.Dr. Marina Cazzaniga reports no competing interests.Dr. Tapashi Dalvi, Dr. Graham Walker, and Dr. James Bennett are employees or contracted employees of AstraZeneca and may own stock.Dr. Shozo Ohsumi has received honoraria for lecture fees from AstraZeneca.